tradingkey.logo

tradingkey.logo
怜玢


Genprex Inc

GNPX
りォッチリストに远加
2.080USD
-0.130-5.88%
終倀 11-13 16:00ET
1.71M時䟡総額
損倱額盎近12ヶ月PER

Genprex Incに぀いお 䌁業名

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

Genprex Inc プロフィヌル


䌁業コヌドGNPX
䌚瀟名Genprex Inc
䞊堎日Mar 29, 2018
最高経営責任者「CEO」Confer (Ryan M)
埓業員数15
蚌刞皮類Ordinary Share
決算期末Mar 29
本瀟所圚地3300 Bee Cave Road, Suite 650-227
郜垂AUSTIN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号78746
電話番号18777744679
りェブサむトhttps://www.genprex.com/
䌁業コヌドGNPX
䞊堎日Mar 29, 2018
最高経営責任者「CEO」Confer (Ryan M)

Genprex Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Mark Stanley Berger, M.D.
Dr. Mark Stanley Berger, M.D.
Chief Medical Officer
Chief Medical Officer
338.00
-190.24%
Mr. Brent M. Longnecker
Mr. Brent M. Longnecker
Independent Director
Independent Director
7.00
-5857.14%
Mr. Ryan M. Confer
Mr. Ryan M. Confer
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
--
--
Mr. Jose Antonio Moreno Toscano
Mr. Jose Antonio Moreno Toscano
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William R. (Will) Wilson, Jr.
Mr. William R. (Will) Wilson, Jr.
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Mark Stanley Berger, M.D.
Dr. Mark Stanley Berger, M.D.
Chief Medical Officer
Chief Medical Officer
338.00
-190.24%
Mr. Brent M. Longnecker
Mr. Brent M. Longnecker
Independent Director
Independent Director
7.00
-5857.14%
Mr. Ryan M. Confer
Mr. Ryan M. Confer
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
--
--
Mr. Jose Antonio Moreno Toscano
Mr. Jose Antonio Moreno Toscano
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William R. (Will) Wilson, Jr.
Mr. William R. (Will) Wilson, Jr.
Independent Director
Independent Director
--
--

よくある質問

Genprex Incの䞊䜍5名の株䞻は誰ですか


Genprex Incの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Mark Stanley Berger, M.D.

Genprex IncGNPXの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Genprex Incの株匏を保有しおいる機関は54瀟あり、保有株匏の総垂堎䟡倀は玄65.88Kで、党䜓の0.63%を占めおいたす。2025Q4ず比范しお、機関の持ち株は30058.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。